MNV
Market News Video
MNV MNV 10 Bargains You Can Buy Cheaper Than Insiders Did
MNV
MNV
MNV
MNV
MNV
MNV
MNV
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

Amicus Therapeutics Enters Oversold Territory (FOLD)
Monday, February 8, 1:24 PM ET, by Market News Video Staff

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy ...

EXACT Sciences is Now Oversold (EXAS)
Tuesday, February 9, 4:24 PM ET, by Market News Video Staff

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy ...

XBI, XON, BXLT, ABBV: Large Outflows Detected at ETF
Tuesday, February 16, 10:53 AM ET, by Market News Video Staff

Symbols mentioned in this story: XBI, XON, BXLT, ABBV Exchange traded funds (ETFs) trade just ...

Relative Strength Alert For PTC Therapeutics
Tuesday, February 23, 11:56 AM ET, by Market News Video Staff

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy ...

Relative Strength Alert For Clovis Oncology
Thursday, February 25, 11:57 AM ET, by Market News Video Staff

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy ...

  More articles:  1 2 3 4 5 6 7 next »

Theravance Inc Breaks Above 200-Day Moving Average - Bullish for THRX

By Market News Video Staff, Thursday, January 10, 4:42 PM ET
Play Video: Learn About The 200 DMA


If the video does not load after a few moments, Upgrade to the Latest Flash Player.

In trading on Thursday, shares of Theravance Inc (THRX) crossed above their 200 day moving average of $23.41, changing hands as high as $23.56 per share. Theravance Inc shares are currently trading up about 3.6% on the day. The chart below shows the one year performance of THRX shares, versus its 200 day moving average:

Theravance Inc 200 Day Moving Average Chart

Looking at the chart above, THRX's low point in its 52 week range is $15.69 per share, with $31.87 as the 52 week high point that compares with a last trade of $23.51.


Special Offer: Find out what Dave Moenning is holding in the ETF Channel Flexible Growth Investment Portfolio with 30 Days Free.

According to the ETF Finder at ETF Channel, THRX makes up 3.18% of the SPDR S&P Biotech ETF (AMEX:XBI) which is trading up by about 0.1% on the day Thursday.

See what other ETFs contain THRX
See what other stocks are held by XBI


Top Six Most Viewed Stories This Week @ Market News Video:

This Article's Word Cloud:   AMEX   Above   According   Biotech   Channel   Crossing   Dave   Days   ETFs   Finder   Growth   Looking   Moenning   SPDR   Special   Start   Stocks   THRX   Their   Theravance   Thursday   about   above   average   below   changing   chart   compares   currently   hands   held   high   last   makes   moving   other   point   range   raquo   share   shares   slideshow   that   trading   versus   week   what   which   with   year
MNV
MNV
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy - Video Widget
MNV
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV
MNV MNV Portfolio Channel Stock Market Definitions
MNV

Theravance Inc Breaks Above 200-Day Moving Average - Bullish for THRX | Market News Video | Copyright © 2008 - 2016, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.